

# SAFETY DATA SHEET

Fluorochrome conjugated antibodies for flow cytometry

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

<b>Product name</b>	: Fluorochrome conjugated antibodies for flow cytometry
<b>Part no.</b>	: C0222, C1001, C7066, C7067, C7099, C7224, C7225, C7226, C7227, C7230, C7238, C7242, C7244, C7246, C7252, C7256, C7278, C7280, C7281, FR044, FR048, FR481, FR700, FR729, FR866, FR867, FR868, FR875, FR881, FR882, FR883, FR894, IF001, IF002, PR701, PR702, PR703, PR704, PR706, PR707, PR710, PR711, PR712, PR713, R0436, R0437, R0439, R0480, R0715, R0745, R0805, R0806, R0807, R0808, R0810, R0811, R0841, R0842, R0843, R0848, R0864, R5111, R5112, R7000, R7012, R7013, R7014, R7058, R7061, R7078, R7086, R7087, R7108, R7125, R7127, R7144, R7145, R7159, R7164, R7188, R7189, R7209, R7219, R7229, R7251, R7267, R7272, R7277, TC051, TC641, TC660, TC661, TC663, TC664, TC665, TC666, TC667, TC668, TC669, TC670, TC671, TC674, TC675, TC677, TC683, TC685, TC686, TC687, TC689, TC690, X0928, X0929, X0930, X0932, X0935, X0949, X0950, X0955, X0956, X0957, X0968, X0978, X0979, X0998

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

<b>Identified uses</b>	: Laboratory use Container type: Bottle C0222 // Polyclonal Rabbit Anti-Human Kappa Light Chains/APC, Rabbit F(ab') <sub>2</sub> // 0.2-100mL C1001 // Monoclonal Mouse Anti-Human Terminal Deoxynucleotidyl Transferase/APC Clone DAK-TDT // 0.5 mL C7066 // Monoclonal Mouse Anti-Human CD19/RPE-Cy5, Clone HD37 // 0.2-100mL C7067 // Monoclonal Mouse Anti-Human CD3/RPE-Cy5, Clone UCHT1 // 0.2-100mL C7099 // Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen/RPE-Cy5, Clone T29/33 // 0.2-100mL C7224 // Monoclonal Mouse Anti-Human CD19/APC, Clone HD37 // 0.2-100mL C7225 // Monoclonal Mouse Anti-Human CD3/APC, Clone UCHT1 // 0.2-100mL C7226 // Monoclonal Mouse Anti-Human CD4/APC, Clone MT310 // 0.2-100mL C7227 // Monoclonal Mouse Anti-Human CD8/APC, Clone DK25 // 0.2-100mL C7230 // Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen/APC, Clone T29/33 // 0.2-100mL C7238 // Monoclonal Mouse Anti-Human CD34 Class III/APC, Clone BIRMA-K3 // 0.2-100mL C7242 // Monoclonal Mouse Anti-Human CD5/APC, Clone DK23 // 0.2-100mL C7244 // Monoclonal Mouse Anti-Human CD117, c-kit/APC, Clone 104D2 // 0.2-100mL C7246 // Monoclonal Mouse Anti-Human Myeloperoxidase/APC, Clone MPO-7 // 0.2-100mL C7252 // Monoclonal Mouse Anti-Human CD79 $\alpha$ /APC, Clone HM57 // 0.2-100mL C7256 // Monoclonal Mouse Anti-Human CD138/APC, Clone MI15 // 0.2-100mL C7278 // Monoclonal Mouse Anti-Human CD64, Fc Gamma Receptor I/APC, Clone 10.1 // 0.2-100mL C7280 // Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/APC, Clone Y2/51 // 0.2-100mL C7281 // Monoclonal Mouse Anti-Human CD22/APC, Clone 4KB128 // 0.2-100mL FR044 // MultiMix Dual-Colour Reagent, Anti-Human Lambda Light Chains/FITC + Anti-Human CD19/RPE // 0.2-100mL FR048 // MultiMix Dual-Colour Reagent, Anti-Human Kappa Light Chains/FITC + Anti-Human CD19/RPE // 0.2-100mL FR481 // MultiMix Dual-Colour Reagent, Anti-Human Kappa Light Chains/FITC + Anti-Human Lambda Light Chains/RPE // 0.2-100mL FR700 // MultiMix Dual-Colour Reagent, Anti-Human CD45/FITC + Anti-Human CD14/RPE // 0.2-100mL FR729 // MultiMix Dual-Colour Reagent, Anti-Human CD5/FITC + Anti-Human CD20/RPE // 0.2-100mL FR866 // MultiMix Dual-Colour Reagent, Anti-Human CD3/FITC + Anti-Human CD19/RPE // 0.2-100mL
------------------------	---

**SECTION 1: Identification of the substance/mixture and of the company/  
undertaking**

FR867 // MultiMix Dual-Colour Reagent, Anti-Human HLA-DP, DQ, DR Antigen/FITC + Anti-Human CD3/RPE // 0.2-100mL  
FR868 // MultiMix Dual-Colour Reagent, Anti-Human CD4/FITC + Anti-Human CD8/RPE // 0.2-100mL  
FR875 // MultiMix Dual-Colour Reagent, Anti-Human CD3/FITC + Anti-Human CD4/RPE // 0.2-100mL  
FR881 // MultiMix Dual-Colour Reagent, Anti-Human CD3/FITC + Anti-Human CD8/RPE // 0.2-100mL  
FR882 // MultiMix Dual-Colour Reagent, Anti-Human CD5/FITC + Anti-Human CD19/RPE // 0.2-100mL  
FR883 // MultiMix Dual-Colour Reagent, Anti-Human CD10/FITC + Anti-Human CD19/RPE // 0.2-100mL  
FR894 // MultiMix Dual-Colour Reagent, Anti-Human CD2/FITC + Anti-Human CD19/RPE // 0.2-100mL  
IF001//Monoclonal Mouse Anti-Human Terminal Deoxynucleotidyl Transferase/iFluor 488 Clone DAK-TDT // 0.5 mL  
IF002//Monoclonal Mouse Anti-Human Terminal Deoxynucleotidyl Transferase/iFluor 700 Clone DAK-TDT // 0.5 mL  
PR701 // Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen/PerCP, Clone 2D1 // 0,2-100mL  
PR702 // Monoclonal Mouse Anti-Human CD3/PerCP, Clone UCHT1 // 0,2-100mL  
PR703 // Monoclonal Mouse anti-Human CD19/PerCP-Cy5.5, clone HD37 // 0,2-100mL  
PR704 // Monoclonal Mouse anti-Human Myeloperoxidase/PerCP-Cy5.5, clone MPO-7 // 0,2-100mL  
PR706 // Monoclonal Mouse anti-Human CD34/PerCP-Cy5.5, clone BIRMA-K3 // 0,2-100mL  
PR707// Monoclonal Mouse Anti-Human CD22/PerCP-Cy5.5 Clone 4KB128 // 0.5 mL  
PR710 // Monoclonal Mouse Anti-Human CD1a/PerCP-Cy5.5 Clone NA1/34 // 0.5 mL  
PR711 // Monoclonal Mouse Anti-Human CD7/PerCP-Cy5.5 Clone CBC.37 // 0.5 mL  
PR712 // Polyclonal Rabbit Anti-Human Lambda Light Chains/PerCP-Cy5.5 // 0.5 mL  
PR713 // Monoclonal Mouse Anti-Human Plasma Cell/PerCP-Cy5.5 Clone VS38c // 0.5 mL  
R0436 // Polyclonal Rabbit Anti-Human Kappa Light Chains/RPE, Rabbit F(ab')2 // 0.2-100mL  
R0437 // Polyclonal Rabbit Anti-Human Lambda Light Chains/RPE, Rabbit F(ab')2 // 0.2-100mL  
R0439 // Polyclonal Rabbit Anti-Mouse Immunoglobulins/RPE, Rabbit F(ab')2 // 0.2-100mL  
R0480 // Polyclonal Goat Anti-Mouse Immunoglobulins/RPE, Goat F(ab')2 // 0.2-100mL  
R0715 // Monoclonal Mouse Anti-Human CD13/RPE, Clone WM-47 // 0.2-100mL  
R0745 // Monoclonal Mouse Anti-Human CD33/RPE, Clone WM-54 // 0.2-100mL  
R0805 // Monoclonal Mouse Anti-Human CD4/RPE, Clone MT310 // 0.2-100mL  
R0806 // Monoclonal Mouse Anti-Human CD8/RPE, Clone DK25 // 0.2-100mL  
R0807 // Monoclonal Mouse Anti-Human CD2/RPE, Clone MT910 // 0.2-100mL  
R0808 // Monoclonal Mouse Anti-Human CD19/RPE, Clone HD37 // 0.2-100mL  
R0810 // Monoclonal Mouse Anti-Human CD3/RPE, Clone UCHT1 // 0.2-100mL  
R0811 // Monoclonal Mouse Anti-Human CD25, Interleukin-2 Receptor/RPE, Clone ACT-1 // 0.2-100mL  
R0841 // Monoclonal Mouse Anti-Human CD11b, C3bi Receptor/RPE, Clone 2LPM19c // 0.2-100mL  
R0842 // Monoclonal Mouse Anti-Human CD5/RPE, Clone DK23 // 0.2-100mL  
R0843 // Monoclonal Mouse Anti-Human CD45R0/RPE, Clone UCHL1 // 0.2-100mL  
R0848 // Monoclonal Mouse Anti-Human CD10/RPE, Clone SS2/36 // 0.2-100mL  
R0864 // Monoclonal Mouse Anti-Human CD14/RPE, Clone TÜK4 // 0.2-100mL  
R5111 // Polyclonal Rabbit Anti-Human IgM/RPE, Rabbit F(ab')2 // 0.2-100mL  
R5112 // Polyclonal Rabbit Anti-Human IgD/RPE, Rabbit F(ab')2 // 0.2-100mL  
R7000 // Monoclonal Mouse Anti-Human HLA-ABC Antigen/RPE, Clone W6/32 // 0.2-100mL  
R7012 // Monoclonal Mouse Anti-Human CD16, Fc Gamma Receptor III/RPE, Clone DJ130c // 0.2-100mL  
R7013 // Monoclonal Mouse Anti-Human CD20/RPE, Clone B-Ly1 // 0.2-100mL  
R7014 // Monoclonal Mouse Anti-Human CD42b, Platelet Glycoprotein Ib/RPE, Clone

**SECTION 1: Identification of the substance/mixture and of the company/  
undertaking**

AN51 // 0.2-100mL  
R7058 // Monoclonal Mouse Anti-Human CD41, Platelet Glycoprotein IIb/RPE, Clone 5B12 // 0.2-100mL  
R7061 // Monoclonal Mouse Anti-Human CD22/RPE, Clone 4KB128 // 0.2-100mL  
R7078 // Monoclonal Mouse Anti-Human CD235a, Glycophorin A/RPE, Clone JC159 // 0.2-100mL  
R7086 // Monoclonal Mouse Anti-Human CD45RA/RPE, Clone 4KB5 // 0.2-100mL  
R7087 // Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen/RPE, Clone T29/33 // 0.2-100mL  
R7108 // Monoclonal Mouse Anti-Human CD23/RPE, Clone MHM6 // 0.2-100mL  
R7125 // Monoclonal Mouse Anti-Human CD34 Class III/RPE, Clone BIRMA-K3 // 0.2-100mL  
R7127 // Monoclonal Mouse Anti-Human CD56/RPE, Clone MOC-1 // 0.2-100mL  
R7144 // Monoclonal Mouse Anti-Human CD38/RPE, Clone AT13/5 // 0.2-100mL  
R7145 // Monoclonal Mouse Anti-Human CD117, c-kit/RPE, Clone 104D2 // 0.2-100mL  
R7159 // Monoclonal Mouse Anti-Human CD79 $\alpha$ /RPE, Clone HM57 // 0.2-100mL  
R7164 // Monoclonal Mouse Anti-Human CD28/RPE, Clone CD28.1 // 0.2-100mL  
R7188 // Monoclonal Mouse Anti-Human CD103, Mucosa Lymphocyte Antigen/RPE, Clone Ber-ACT8 // 0.2-100mL  
R7189 // Monoclonal Mouse Anti-Human CD1a/RPE, Clone NA1/34 // 0.2-100mL  
R7209 // Monoclonal Mouse Anti-Human Myeloperoxidase/RPE, Clone MPO-7 // 0.2-100mL  
R7219 // Monoclonal Mouse Anti-Human CD64, Fc Gamma Receptor I/RPE, Clone 10.1 // 0.2-100mL  
R7229 // Monoclonal Mouse Anti-Human CD138/RPE, Clone MI15 // 0.2-100mL  
R7251 // Monoclonal Mouse Anti-Human CD56/RPE, Clone C5.9 // 0.2-100mL  
R7267 // Monoclonal Mouse Anti-Human HLA-DR Antigen/RPE, Clone AB3 // 0.2-100mL  
R7272 // Monoclonal Mouse Anti-Human CD79 $\beta$ /RPE, Clone SN8 // 0.2-100mL  
R7277 // Monoclonal Mouse Anti-Human CD7/RPE, Clone CBC.37 // 0.2-100mL  
TC051 // MultiMix Triple-Colour Reagent, Anti-Human Kappa Light Chains/FITC + Anti-Human Lambda Light Chains/RPE + Anti-Human CD19/RPE-Cy5 // 0.2-100mL  
TC641 // MultiMix Triple-Colour Reagent, Anti-Human CD8/FITC + Anti-Human CD4/RPE + Anti-Human CD3/RPE-Cy5 // 0.2-100mL  
TC660 // MultiMix Triple-Colour Reagent, Anti-Human CD8/FITC + Anti-Human CD4/RPE + Anti-Human CD3/APC // 0.2-100mL  
TC661 // MultiMix Triple-Colour Reagent, Anti-Human CD16/FITC + Anti-Human CD56/RPE + Anti-Human CD3/APC // 0.2-100mL  
TC663 // MultiMix Triple-Colour Reagent, Anti-Human CD20/FITC + Anti-Human CD5/RPE + Anti-Human CD19/APC // 0.2-100mL  
TC664 // MultiMix Triple-Colour Reagent, Anti-Human CD5/FITC + Anti-Human CD10/RPE + Anti-Human CD19/APC // 0.2-100mL  
TC665 // MultiMix Triple-Colour Reagent, Anti-Human CD103/FITC + Anti-Human CD11c/RPE + Anti-Human CD19/APC // 0.2-100mL  
TC666 // MultiMix Triple-Colour Reagent, Anti-Human CD2/FITC + Anti-Human CD34 Class III/RPE + Anti-Human CD5/APC // 0.2-100mL  
TC667 // MultiMix Triple-Colour Reagent, Anti-Human MPO/FITC + Anti-Human CD79 $\alpha$ /RPE + Anti-Human CD3/APC // 0.2-100mL  
TC668 // MultiMix Triple-Colour Reagent, Anti-Human TdT/FITC + Anti-Human CD22/RPE + Anti-Human CD3/APC // 0.2-100mL  
TC669 // MultiMix Triple-Colour Reagent, Anti-Human CD19/FITC + Anti-Human Lambda Light Chains/RPE + Anti-Human Kappa Light Chains/APC // 0.2-100mL  
TC670 // MultiMix Triple-Colour Reagent, Anti-Human Plasma Cell/FITC + Anti-Human Lambda Light Chains/RPE + Anti-Human Kappa Light Chains/APC // 0.2-100mL  
TC671 // MultiMix Triple-Colour Reagent, Anti-Human CD38/FITC + Anti-Human CD56/RPE + Anti-Human CD45/APC // 0.2-100mL  
TC674 // MultiMix Triple-Colour Reagent, Anti-Human CD38/FITC + Anti-Human CD56/RPE + Anti-Human CD19/APC // 0.2-100mL  
TC675 // MultiMix Triple-Colour Reagent, Anti-Human CD71/FITC + Anti-Human CD235a/RPE + Anti-Human CD45/APC // 0.2-100mL  
TC677 // MultiMix Triple-Colour Reagent, Anti-Human CD2/FITC + Anti-Human CD7/RPE + Anti-Human CD3/APC // 0.2-100mL  
TC683 // MultiMix Triple-Colour Reagent, Anti-Human B Cell (FMC7)/FITC + Anti-

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

Human CD23/RPE + Anti-Human CD19/APC // 0.2-100mL  
 TC685 // MultiMix Triple-Colour Reagent, Anti-Human CD13/FITC + Anti-Human HLA-DR Antigen/RPE + Anti-Human CD117/APC // 0.2-100mL  
 TC686 // MultiMix Triple-Colour Reagent, Anti-Human CD33/FITC + Anti-Human CD34/RPE + Anti-Human CD117/APC // 0.2-100mL  
 TC687 // MultiMix Triple-Colour Reagent, Anti-Human CD41/FITC + Anti-Human CD34/RPE + Anti-Human CD61/APC // 0.2-100mL  
 TC689 // MultiMix Triple-Colour Reagent, Anti-Human CD19/FITC + Anti-Human CD34/RPE + Anti-Human CD22/APC // 0.2-100mL  
 TC690 // MultiMix Triple-Colour Reagent, Anti-Human CD3/FITC + Anti-Human CD19/RPE + Anti-Human CD45/APC // 0.2-100mL  
 X0928 // Control Reagent, Mouse IgG1/RPE // 0.2-100mL  
 X0929 // Ig Reagent Rabbit F(ab')<sub>2</sub>/FITC // 0.2-100mL  
 X0930 // Control Reagent, Rabbit F(ab')<sub>2</sub>/RPE // 0.2-100mL  
 X0932 // MultiMix Dual-Colour Control Reagent, Mouse IgG1/FITC + Mouse IgG1/RPE // 0.2-100mL  
 X0935 // MultiMix Dual-Colour Control Reagent, Rabbit F(ab')<sub>2</sub>/FITC + Rabbit F(ab')<sub>2</sub>/RPE // 0.2-100mL  
 X0949 // MultiMix Dual-Colour Control Reagent, Mouse IgG1/FITC + Mouse IgG2a/RPE // 0.2-100mL  
 X0950 // Control Reagent, Mouse IgG2a/RPE // 0.2-100mL  
 X0955 // Control Reagent, Mouse IgG1/RPE-Cy5 // 0.2-100mL  
 X0956 // MultiMix Triple-Colour Control Reagent, Mouse IgG1/FITC + Mouse IgG1/RPE + Mouse IgG1/RPE-Cy5 // 0.2-100mL  
 X0957 // MultiMix Triple-Colour Control Reagent, Rabbit F(ab')<sub>2</sub>/FITC + Rabbit F(ab')<sub>2</sub>/RPE + Mouse IgG1/RPE-Cy5 // 0.2-100mL  
 X0968 // Control Reagent, Mouse IgG1/APC // 0.2-100mL  
 X0978 // MultiMix Triple-Colour Control Reagent, Mouse IgG1/FITC + Mouse IgG1/RPE + Mouse IgG1/APC // 0.2-100mL  
 X0979 // MultiMix Triple-Colour Control Reagent, Mouse IgG1/FITC + Rabbit F(ab')<sub>2</sub>/RPE + Rabbit F(ab')<sub>2</sub>/APC // 0.2-100mL  
 X0998 // Control Reagent, Rabbit F(ab')<sub>2</sub>/APC // 0.2-100mL  
 Reference number: SDS402

**Uses advised against** : None known.

### 1.3 Details of the supplier of the safety data sheet

Agilent Technologies, Inc.  
 5301 Stevens Creek Blvd  
 Santa Clara, CA 95051, USA  
 Tel: +1 800 227 9770

Agilent Technologies Singapore (International) Pte Ltd.  
 No. 1 Yishun Avenue 7  
 Singapore, 768923  
 Tel. (65) 6276 2622

Agilent Technologies Denmark ApS  
 Produktionsvej 42  
 2600 Glostrup,  
 Denmark  
 Tel. +45 44 85 95 00

www.Agilent.com

**e-mail address of person responsible for this SDS** : sds@agilent.com

### 1.4 Emergency telephone number

**Emergency telephone number (with hours of operation)** : CHEMTREC®: +(44)-870-8200418

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

**Product definition** : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

**Ingredients of unknown toxicity** : Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1 - 10%  
Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%  
Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%

**Ingredients of unknown ecotoxicity** : Contains 1% of components with unknown hazards to the aquatic environment

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

**Signal word** : No signal word.

**Hazard statements** : No known significant effects or critical hazards.

#### Precautionary statements

**Prevention** : Not applicable.

**Response** : Not applicable.

**Storage** : Not applicable.

**Disposal** : Not applicable.

**Supplemental label elements** : Not applicable.

**Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles** : Not applicable.

#### Special packaging requirements

**Tactile warning of danger** : Not applicable.

### 2.3 Other hazards

**Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII** : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**Other hazards which do not result in classification** : None known.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

#### Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

### 5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous combustion products** : Decomposition products may include the following materials:  
carbon dioxide  
carbon monoxide  
nitrogen oxides  
sulfur oxides

## SECTION 5: Firefighting measures

### 5.3 Advice for firefighters

- Special precautions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- 6.2 Environmental precautions** : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### 6.3 Methods and material for containment and cleaning up

- Methods for cleaning up** : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

- 6.4 Reference to other sections** : See Section 1 for emergency contact information.  
See Section 8 for information on appropriate personal protective equipment.  
See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

- Storage** : Specific storage conditions: Please consult the label.  
Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s)

- Recommendations** : Industrial applications, Professional applications.

## SECTION 7: Handling and storage

**Industrial sector specific solutions** : Not available.

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational exposure limits

No exposure limit value known.

#### Biological exposure indices

No exposure indices known.

**Recommended monitoring procedures** : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### DNELs/DMELs

No DNELs/DMELs available.

#### PNECs

No PNECs available

### 8.2 Exposure controls

**Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### Individual protection measures

**Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

#### Skin protection

**Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

**Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.



**SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

**9.1 Information on basic physical and chemical properties**

Appearance

- Physical state** : Liquid.
- Colour** : FITC conjugates: Yellow. (Light) / Green.  
RPE and PerCP conjugates: Red.  
RPE-Cy5 conjugates: Purple.  
PerCP-Cy5.5 conjugates: Brown.  
APC conjugates: Blue.

**Odour** : Not available.

**Odour threshold** : Not available.

**Melting point/freezing point** : 0°C

**Initial boiling point and boiling range** : 100°C

**Flammability** : Not applicable.

**Upper/lower flammability or explosive limits** : Not available.

**Flash point** : Not available.

**Auto-ignition temperature** : Not available.

**Decomposition temperature** : Not available.

**pH** : 7.2

**Viscosity** : Not available.

<b>Solubility(ies)</b>	<b>Media</b>	<b>Result</b>
	water	Soluble

**Miscible with water** : Yes.

**Partition coefficient: n-octanol/water** : Not applicable.

<b>Vapour pressure</b>	<b>Vapour Pressure at 20°C</b>			<b>Vapour pressure at 50°C</b>			
	<b>Ingredient name</b>	<b>mm Hg</b>	<b>kPa</b>	<b>Method</b>	<b>mm Hg</b>	<b>kPa</b>	<b>Method</b>
	water	17.5	2.3	-	92.258	12.3	-

**Evaporation rate** : Not available.

**Relative density** : Not available.

**Vapour density** : Not available.

**Explosive properties** : Not available.

**Oxidising properties** : Not available.

Particle characteristics

**Median particle size** : Not applicable.

**9.2 Other information**

No additional information.

## SECTION 10: Stability and reactivity

- 10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.
- 10.2 Chemical stability** : The product is stable.
- 10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.
- 10.4 Conditions to avoid** : No specific data.
- 10.5 Incompatible materials** : May react or be incompatible with oxidising materials.
- 10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

#### Acute toxicity

Not available.

#### Acute toxicity estimates

N/A

#### Irritation/Corrosion

**Conclusion/Summary** : Not available.

#### Sensitiser

**Conclusion/Summary** : Not available.

#### Mutagenicity

**Conclusion/Summary** : Not available.

#### Carcinogenicity

**Conclusion/Summary** : Not available.

#### Reproductive toxicity

**Conclusion/Summary** : Not available.

#### Teratogenicity

**Conclusion/Summary** : Not available.

#### Specific target organ toxicity (single exposure)

Not available.

#### Specific target organ toxicity (repeated exposure)

Not available.

#### Aspiration hazard

Not available.

**Information on likely routes of exposure** : Not available.

#### Potential acute health effects

**Inhalation** : No known significant effects or critical hazards.

**Ingestion** : No known significant effects or critical hazards.

**Skin contact** : No known significant effects or critical hazards.

**Eye contact** : No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical and toxicological characteristics

**Inhalation** : No specific data.

## SECTION 11: Toxicological information

**Ingestion** : No specific data.

**Skin contact** : No specific data.

**Eye contact** : No specific data.

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

#### Short term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

#### Long term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Potential chronic health effects

**Conclusion/Summary** : Not available.

**General** : No known significant effects or critical hazards.

**Carcinogenicity** : No known significant effects or critical hazards.

**Mutagenicity** : No known significant effects or critical hazards.

**Reproductive toxicity** : No known significant effects or critical hazards.

## 11.2 Information on other hazards

### 11.2.1 Endocrine disrupting properties

Not available.

### 11.2.2 Other information

Not available.

## SECTION 12: Ecological information

### 12.1 Toxicity

**Conclusion/Summary** : Not available.

### 12.2 Persistence and degradability

Not available.

### 12.3 Bioaccumulative potential

Not available.

### 12.4 Mobility in soil

**Soil/water partition coefficient ( $K_{oc}$ )** : Not available.

**Mobility** : Not available.

### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### 12.6 Endocrine disrupting properties

Not available.

### 12.7 Other adverse effects

**Fluorochrome conjugated antibodies for flow cytometry**

**SECTION 12: Ecological information**

No known significant effects or critical hazards.

**SECTION 13: Disposal considerations**

**13.1 Waste treatment methods**

Product

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

Packaging

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

**SECTION 14: Transport information**

	<b>ADR/RID</b>	<b>IMDG</b>	<b>IATA</b>
<b>14.1 UN number or ID number</b>	Not regulated.	Not regulated.	Not regulated.
<b>14.2 UN proper shipping name</b>	-	-	-
<b>14.3 Transport hazard class(es)</b>	-	-	-
<b>14.4 Packing group</b>	-	-	-
<b>14.5 Environmental hazards</b>	No.	No.	No.

Additional information

**14.6 Special precautions for user** : **Transport within user’s premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**14.7 Transport in bulk according to IMO instruments** : Not available.

**SECTION 15: Regulatory information**

**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

## SECTION 15: Regulatory information

None of the components are listed.

### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

**Label** : Not applicable.

#### Other EU regulations

##### Ozone depleting substances (1005/2009/EU)

Not listed.

##### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

##### Persistent Organic Pollutants

Not listed.

##### Seveso Directive

This product is not controlled under the Seveso Directive.

#### International regulations

##### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

##### Montreal Protocol

Not listed.

##### Stockholm Convention on Persistent Organic Pollutants

Not listed.

##### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

##### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

#### Inventory list

<b>Australia</b>	: Not determined.
<b>Canada</b>	: Not determined.
<b>China</b>	: Not determined.
<b>Eurasian Economic Union</b>	: <b>Russian Federation inventory</b> : Not determined.
<b>Japan</b>	: <b>Japan inventory (CSCL)</b> : Not determined. <b>Japan inventory (ISHL)</b> : Not determined.
<b>New Zealand</b>	: Not determined.
<b>Philippines</b>	: Not determined.
<b>Republic of Korea</b>	: Not determined.
<b>Taiwan</b>	: Not determined.
<b>Thailand</b>	: Not determined.
<b>Turkey</b>	: Not determined.
<b>United States</b>	: Not determined.
<b>Viet Nam</b>	: Not determined.

**15.2 Chemical safety assessment** : This product contains substances for which Chemical Safety Assessments might still be required.

## SECTION 16: Other information

✔ Indicates information that has changed from previously issued version.

**Abbreviations and acronyms** : ATE = Acute Toxicity Estimate  
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]  
DMEL = Derived Minimal Effect Level  
DNEL = Derived No Effect Level  
EUH statement = CLP-specific Hazard statement  
N/A = Not available  
PBT = Persistent, Bioaccumulative and Toxic  
PNEC = Predicted No Effect Concentration  
RRN = REACH Registration Number  
vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

### Full text of abbreviated H statements

Not applicable.

### Full text of classifications [CLP/GHS]

Not applicable.

**Date of issue/ Date of revision** : 15/09/2023

**Date of previous issue** : No previous validation

**Version** : 1

### Notice to reader

**Disclaimer:** The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.